China Resources Pharmaceutical Group's (HKG:3320) subsidiary KPC Pharmaceuticals (SHA:600422) recorded net profit attributable to the shareholders of 648.1 million yuan in 2024, 46% higher than 444.7 million yuan logged before retrospective adjustment in 2023, a Monday bourse filing said.
KPC Pharmaceuticals' basic earnings per share for the reporting year were 0.86 yuan compared with 0.59 yuan per share recorded for the previous year.
The total operating revenue of the said subsidiary for the year was noted at 8.40 billion yuan, 9.1% higher than 7.70 billion yuan from a year ago.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.